Tempest Therapeutics Advances CAR-T Pipeline with Positive Data, Manufacturing Deal
Event summary
- Tempest reported 100% complete response rate in 15 CAR-T-naïve patients across REDEEM-1 and POEMS-1 trials for TPST-2003.
- Selected Cincinnati Children’s AGCTC as lead manufacturing partner for TPST-2003, with lentiviral vector delivery completed.
- Appointed Andrew Fang, Ph.D., as Head of Business Development to expand strategic partnerships, particularly in China.
- Closed $2 million private placement with potential for additional $4 million upon warrant exercise.
- Reported $27.7 million net loss for Q1 2026, primarily due to asset acquisition costs.
The big picture
Tempest’s progress in its lead CAR-T program TPST-2003 positions it in the competitive landscape of next-generation cancer therapies. The company’s strategic moves—securing a manufacturing partner and expanding business development efforts—reflect broader industry trends toward outsourcing production and seeking cross-border partnerships to accelerate development. The $2 million private placement, though modest, suggests continued investor interest despite significant financial losses tied to asset acquisitions.
What we're watching
- Clinical Efficacy
- Whether the 100% complete response rate in early trials for TPST-2003 can be sustained in larger, registrational studies.
- Manufacturing Scalability
- The pace at which Cincinnati Children’s AGCTC can scale production of TPST-2003 to support planned registrational trials.
- Strategic Partnerships
- How Andrew Fang’s focus on China will impact Tempest’s ability to secure licensing deals or corporate transactions.
Related topics